Myeloid Derived Suppressor and Dendritic Cell Subsets Are Related to Clinical Outcome in Prostate Cancer Patients Treated With Prostate GVAX and Ipilimumab

Journal for ImmunoTherapy of Cancer - United Kingdom
doi 10.1186/s40425-014-0031-3
Full Text
Abstract

Available in full text

Date
Authors
Publisher

BMJ

Related search

Myeloid Derived Suppressor Cells: Subsets, Expansion, and Role in Cancer Progression

2012English

Human Miscarriage Is Associated With Dysregulations in Peripheral Blood-Derived Myeloid Dendritic Cell Subsets

Frontiers in Immunology
AllergyImmunology
2019English

Circulating and Tumor-Infiltrating Myeloid Cell Subsets in Patients With Bladder Cancer

International Journal of Cancer
Cancer ResearchOncology
2011English

Dendritic Cell-Based Immunotherapy for Prostate Cancer

CA - A Cancer Journal for Clinicians
OncologyHematology
1999English

Myeloid-Derived Suppressor Cell Subsets Drive Glioblastoma Growth in a Sex-Specific Manner

2020English

Health Related Quality of Life in Patients Treated With Multimodal Therapy for Prostate Cancer

Journal of Urology
Urology
2008English

Radiation-Induced Complications in Prostate Cancer Patients Treated With Radiotherapy

2014English

Predicting Clinical Outcome of Therapy-Resistant Prostate Cancer

Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
2019English

Permanent Prostate Brachytherapy Monotherapy With I-125 for Low- And Intermediate-Risk Prostate Cancer: Outcome in 966 Patients

International Journal of Radiation Oncology Biology Physics
OncologyRadiologyCancer ResearchRadiationNuclear MedicineImaging
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy